MAIA Biotechnology, Inc. MAIA
1.04 USD -0.10 (-8.77%)
At closeNov 6, 2026, 7:12 AM EST
1.05 +0.01 +0.96%
Pre-market · Nov 6, 7:12 AM ET
1.03 Day range 1.10
0.87 52-week range 3.19
- YTD
- -32.03%
- 1 year
- -5.45%
- Market cap
- 64.21M
- EPS (ttm)
- -0.62
- Shares out
- 25.33M
- Forward P/E
- -1.25
- YTD return
- -32.03%
- 1-year return
- -5.45%
- Volume
- 345.69K
- Avg volume
- 449.95K
- Open
- 1.12
- Previous close
- 1.14
- Day's range
- 1.03 – 1.10
- 52-week range
- 0.87 – 3.19
- Beta
- 0.34
- Analysts
- Strong Buy
- Price target
- 12.63 (+1113.9%)
YTD -0.56 (-35.00%)
Key statistics
- Enterprise value
- 51.06M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 70.36
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -8.81M
- Total cash
- 11.58M
- Total debt
- 0
- Return on equity
- -559.56%
- Short % of float
- 3.30%
- 50-day average
- 2.41
- 200-day average
- 2.83
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 12.63 +1113.9% upside
Now 1.04
- Target (low)
- 11.25
- Target (mean)
- 12.63
- Target (high)
- 14.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.35.
Financials — quick view
MAIA Revenue — quarterly 0
MAIA Net income — quarterly -7.94M
MAIA EPS — quarterly -0.13
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 21, 2023 | Noble Capital Markets | init | — | Outperform |
About MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- maiabiotech.com
News
Alpha Buying: 4 Biotech Stocks Insiders Are Betting On 
MAIA Biotechnology Completes Enrollment Of Patients For Part C Of Phase 2 Study Of Ateganosine Sequenced With CPI Cemiplimab To Treat Non-Small Cell Lung Cancer 
MAIA Biotechnology Files Resale Prospectus For 751,879 Shares Issued Under Clinical Trial Funding Agreement 
MAIA Biotechnology Receives Regulatory Approval By The Spanish Agency For Medicines And Medical Devices And Portugal’s National Authority Of Medicines And Health Products To Begin Screening Patients For Its Ongoing Pivotal Phase 3 THIO-104 Clinical Trial In Non-Small Cell Lung Cancer 
MAIA Biotechnology Says First US Patient Dosed In Phase 2 THIO-101 Trial Expansion Evaluating Telomere-Targeting Lead Candidate, Ateganosine, In Third-Line Non-Small Cell Lung Cancer - MAIA Biotechnology CEO Vlad Vitoc Buys 73K Shares At An Average Price Of $1.37 Per Share; Board Member Ramiro Guerrero Buys 185,078 Shares At An Average Price Of $1.36 Per Share
12 Health Care Stocks Moving In Tuesday's After-Market Session - MAIA Biotechnology Q2 EPS $(0.13) Misses $(0.11) Estimate
MAIA Biotechnology Reports 90.5% Disease Control Rate In Phase 2 THIO-101 Clinical Trial Of Ateganosine For Advanced Non-Small Cell Lung Cancer - MAIA Biotechnology Completes Global Enrollment In Part C Of Its Phase 2 THIO-101 Expansion Study Of Ateganosine To Treat Advanced Non-Small Cell Lung Cancer
Your note
Sign in to keep a note on MAIA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHAOUKI STEVEN M | Director | Purchase | Mar 13, 2024 | 88,891 |
| GUERRERO RAMIRO | Director | Purchase | Dec 12, 2024 | 514,970 |
| LOUIE NGAR YEE | Director | Purchase | Apr 24, 2024 | 1,167,190 |
| LUPUT CRISTIAN | Director | Purchase | Oct 31, 2024 | 389,483 |
| MCGUIRE JOSEPH F | Chief Financial Officer | Purchase | Apr 26, 2023 | 9,400 |
| SMITH STAN V | Director | Purchase | Oct 31, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 2.24% | 566,374 | 1.12M | Sep 29, 2024 |
| Halter Ferguson Financial Inc. | 1.49% | 376,714 | 742.13K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.76% | 192,563 | 379.35K | Sep 29, 2024 |
| Blackrock Inc. | 0.31% | 79,727 | 157.06K | Sep 29, 2024 |
| Centric Wealth Management | 0.27% | 68,219 | 134.39K | Sep 29, 2024 |
| Bridgeway Capital Management, Inc. | 0.18% | 45,700 | 90.03K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.59% | 401,588 | 791.13K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.61% | 153,385 | 302.17K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.43% | 108,755 | 214.25K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.18% | 45,700 | 90.03K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.14% | 36,051 | 71.02K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.12% | 29,164 | 57.45K | Oct 30, 2024 |